Pathway Discovery in Macular Degeneration Using Genome-Wide Proteome, Transcriptome, and Epigenetic Analyses
About the Research Project
Program
Award Type
Standard
Award Amount
$100,000
Active Dates
April 01, 2010 - March 31, 2013
Grant ID
M2010040
Co-Principal Investigator(s)
Kent Bailey, PhD, Mayo Clinic Rochester
Goals
We are identifying the molecular biological pathways altered by the genetic variants across the ARMS2 genomic region, or locus, in human retina. This study uses sophisticated “omics” approaches to accomplish these goals.
Summary
The biological pathways affected by the ARMS2 locus increase the odds of developing age-related macular degeneration (AMD) about 7-fold in homozygotes for the risk haplotype compared to the common non-risk haplotype. However, the mechanisms through which the genetic variants at the locus are mediated are controversial. Traditional genetic and biochemical methods have yet to identify the biological pathway through which the impact on disease risk is mediated. Indeed, it is unknown if the genetic risk is mediated through the hypothetical gene LOC387715, HTRA1, or perhaps some mechanisms unrelated to either. In order to identify the biological pathways altered by the genetic variants across this locus, we propose to compare the proteome and transcriptome of retinal tissue from donors homozygous for either the common protective or the risk haplotypes at the ARMS2 locus. Further, this project will provide insight and help determine the value of such so-called “omics” approaches for studying the pathophysiology of complex traits affecting the eye.
Grants
Related Grants
Macular Degeneration Research
The Novel Role of an Intracellular Nuclear Receptor in AMD Pathogenesis
Active Dates
July 01, 2024 - June 30, 2026
Principal Investigator
Neetu Kushwah, PhD
Current Organization
Boston Children’s Hospital
The Novel Role of an Intracellular Nuclear Receptor in AMD Pathogenesis
Active Dates
July 01, 2024 - June 30, 2026

Principal Investigator
Neetu Kushwah, PhD
Current Organization
Boston Children’s Hospital
Macular Degeneration Research
Exploring How NRF2 Protein Reduces RPE Cell Damage by Cigarette Smoke
Active Dates
July 01, 2024 - June 30, 2026
Principal Investigator
Krishna Singh, PhD
Current Organization
Johns Hopkins University School of Medicine
Exploring How NRF2 Protein Reduces RPE Cell Damage by Cigarette Smoke
Active Dates
July 01, 2024 - June 30, 2026

Principal Investigator
Krishna Singh, PhD
Current Organization
Johns Hopkins University School of Medicine
Macular Degeneration Research
The Development of a Transplant-Independent Therapy for RPE Dysfunction
Active Dates
July 01, 2024 - June 30, 2026
Principal Investigator
Shintaro Shirahama, MD, PhD
Current Organization
Schepens Eye Research Institute of Massachusetts Eye and Ear
The Development of a Transplant-Independent Therapy for RPE Dysfunction
Active Dates
July 01, 2024 - June 30, 2026

Principal Investigator
Shintaro Shirahama, MD, PhD
Current Organization
Schepens Eye Research Institute of Massachusetts Eye and Ear